Therapy

Findings Say Goserelin/Tamoxifen Outcomes Good

Published in Cancer Weekly, March 14th, 2000

Study findings suggest that premenopausal women with breast cancer may want to investigate the combination goserelin/tamoxifen therapy.

A study presented at the 22^nd Annual San Antonio Breast Cancer Symposium by researchers from the University of Vienna indicates that this therapy is significantly more effective than cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy.

The researchers compared the efficacy of the goserelin/tamoxifen therapy with CMF therapy in 1,045 premenopausal patients with estrogen and/or progesterone receptor-positive breast cancer.

Patients were chosen at random to receive either...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-03-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry